New insider activity at Arrowhead Pharmaceuticals ( (ARWR) ) has taken place on December 9, 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Director Michael S. Perry has recently sold 16,250 shares of Arrowhead Pharmaceuticals stock, amounting to a total transaction value of $991,737.
Recent Updates on ARWR stock
Arrowhead Pharmaceuticals has experienced significant developments recently, with the FDA approval of Rodemplo marking a major milestone as the company transitions to a commercial stage. This approval, along with robust financial performance, has been pivotal in shaping the company’s outlook. Arrowhead reported a substantial increase in revenue to $829 million, driven by strategic collaborations and milestone payments, including a $200 million payment from Sarepta and another from Novartis. Despite these achievements, the company faces challenges, such as potential competition from generic versions of its products and delays in its obesity program timelines. Additionally, uncertainty remains regarding regulatory claims for pancreatitis risk reduction for Rodemplo. These factors have influenced market perceptions and price target adjustments, as analysts weigh the company’s strong financial position and innovative pipeline against the risks and challenges it faces.
Spark’s Take on ARWR Stock
According to Spark, TipRanks’ AI Analyst, ARWR is a Neutral.
Arrowhead Pharmaceuticals’ overall stock score is driven by strong technical momentum and positive developments in its clinical pipeline and partnerships. However, significant financial challenges and valuation concerns weigh heavily on the score. The earnings call provided a cautiously optimistic outlook, but the company’s financial performance remains a critical area for improvement.
To see Spark’s full report on ARWR stock, click here.
More about Arrowhead Pharmaceuticals
YTD Price Performance: 249.11%
Average Trading Volume: 2,371,451
Technical Sentiment Signal: Buy
Current Market Cap: $8.34B